Atopic Dermatitis

The international observational study aims to understand how moderate to severe AD affects children under 12 years of age, particularly in terms of height, weight, and BMI.

Lio delves into his American Academy of Dermatology Annual Meeting session, "Dietary Triggers and Modifications of Common Dermatologic Conditions: An Evidence Based Approach."

New data was presented at the American Academy of Dermatology Annual Meeting in San Diego, California.

Alphyn’s first-in-class therapeutic is designed to treat the immune system component, and more specifically the bacterial component, of AD.

In addition to the announcement of positive data, Apogee said the trial has already exceeded its objectives ahead of schedule.

Nitin Joshi, PhD, shared CAGE Bio’s development of CGB-500 and why phase 2 EASI scores have the company’s scientific advisory board optimistic.

Test your knowledge on the AAD's recommendations for phototherapy, monoclonal antibodies, JAK inhibitors, and systemic therapies in the latest guidelines.

Raj Chovatiya, MD, PhD, gives a sneak peek of what to expect in atopic dermatitis education at the 2024 American Academy of Dermatology (AAD) Meeting in San Diego, California March 8-12. Since the last meeting, the AAD has released new guidelines to treat the condition.

Researchers have found Staphylococcus aureus may trigger itchiness in atopic dermatitis, opening the door to new treatment approaches in the future.

Learn more about dupilumab-induced conjunctivitis rates and misconceptions, the thriving long-term efficacy of dupilumab over 3 years, and unraveling the itch-flare dynamic in abrocitinib treatment.

The FDA has also granted nemolizumab Priority Review for prurigo nodularis.

Tapinarof cream demonstrated highly statistically significant improvement in the primary end point of vIGA-AD treatment success over vehicle at week 8.

Interim data from the clinical trial was presented in a poster at the South Beach Symposium, with itch reduction demonstrating immediacy and long-term capability.

A discussion among roundtable participants revolved around the importance of effective communication, the impact of prolonged use of topical steroids, and the need for trust building in recommending novel treatment options.

Exposure led to an increase in total plasma IgE levels but reduced epidermal thickening, mast cell number, and plasma histamine levels in the early stages of AD.

Atopic dermatitis flares are about more than just skin symptoms and are difficult to quantify, according to a study that asked patients to describe them.

Researchers explored the efficacy of a multistep treatment strategy in a younger patient population.

Investigators highlighted the importance of considering household second hand smoke exposure when evaluating adolescents with AD.

In a review of relevant research, investigators found that in many aspects, telemedicine services were as effective as in-office care visits for AD.

Functional magnetic resonance imaging response was utilized to test motor, somatosensory association cortex, perception, and sensory integration processing in a recent study.

Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, review the study results for the ADORING 1 and ADORING 2 trials, as well as share closing thoughts on the use of tapinarof in management of AD.

Raj Chovatiya, MD, PhD, and Adelaide A. Hebert, MD, FAAD, comment on the tolerability and low discontinuation rates of tapinarof for patients in AD clinical trials, as well as discuss the adverse events associated with the drug.

In a recent Dermatology Times Case-Based Roundtable Meeting, Tina Bhutani, MD, MAS, shared intriguing cases and insights about atopic dermatitis treatment challenges faced by patients with different lifestyles and hobbies.

A study explored the prioritization habits of both patients with atopic dermatitis and their caregivers when it comes to treatment.

In a recent study, prenatal opioid exposure was also linked to increased odds of infections and asthma, but not with allergies, anaphylaxis, orautoimmune conditions.